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Dietary iron and blood pressure
Iron intake may affect blood pressure, but further confirmation is needed
Nutritional and lifestyle factors are key determinants of 
blood pressure across populations, and lifestyle modi-
fications—including weight reduction if overweight or 
obese, reduced dietary sodium intake, increased dietary 
potassium intake, moderation of alcohol consumption, 
adoption of the DASH (dietary approaches to stop 
hypertension) diet, and regular aerobic exercise—are 
effective at reducing blood pressure.1
In the linked study (doi: 10.1136/bmj.a258), Tzoulaki 
and colleagues assess the association between iron and 
red meat intake and blood pressure using data from the 
international collaborative study of macro-/micronutri-
ents and blood pressure (INTERMAP), a large cross 
sectional study of the nutritional determinants of blood 
pressure across 17 population samples from Japan, 
China, the United Kingdom, and the United States.2 The 
authors found significant inverse associations between 
intake of total iron and non-haem iron and systolic blood 
pressure. Conversely, intake of red meat was significantly 
associated with increased systolic blood pressure, but 
the association between intake of haem iron and blood 
pressure was not significant.
Substantial experimental evidence has linked iron 
overload with accelerated atherosclerosis, and diets 
deficient in iron have been linked with reduced athero-
sclerosis,3 but whether there is a link between iron 
and coronary heart disease is still uncertain. Firstly, 
meta-analyses of the association of biomarkers of iron 
metabolism—such as ferritin and transferrin saturation—
with coronary risk have mostly found no associations.4 
 Secondly, a large randomised controlled trial in which 
phlebotomy was used to reduce iron stores in patients 
with symptomatic peripheral arterial disease found that 
iron reduction had no effect on cardiovascular end 
points,5 although iron reduction may have been ben-
eficial at younger ages. Thirdly, mutations in the gene 
encoding the hereditary haemochromatosis protein 
(HFE) do not seem to be associated with the risk of heart 
disease,6 possibly as a result of lower concentrations of 
low density lipoprotein cholesterol in  people with HFE 
mutations.7 Lastly, prospective studies have also failed 
to show a clear association between iron intake and the 
development of coronary heart  disease.8 Interestingly, 
the pattern seen in the health professionals’ follow-up 
study was similar to the pattern seen in INTERMAP: an 
inverse association for total iron and positive association 
for haem iron in relation to the risk of coronary heart 
disease.8
The study by Tzoulaki and colleagues provides new 
data that underline the complexity of the association 
between iron and heart disease.2 The authors studied 
intake of haem and non-haem iron  separately, because 
these two types of iron have different sources and 
pharmacokinetics, which affects their absorption and 
bioavailability. Non-haem iron comes mostly from veg-
etable foods, whereas haem iron is derived mostly from 
animal sources, mainly meat and  seafood.  Furthermore, 
healthy people adapt to reduce the absorption of non-
haem iron but not haem iron in response to iron sup-
plementation.9
The mechanistic explanation for an inverse association 
between non-haem iron and blood pressure, however, is 
unclear. Iron is a highly reactive metal that is easily oxi-
dised and reduced and which may participate in the gen-
eration of powerful oxidant species. Indeed, iron induced 
oxidative stress has been hypothesised as a primary 
mechanism in diabetes associated with iron overload.10 
Even moderately raised iron stores and plasma ferritin 
concentrations, below those seen in haemochromatosis, 
might be associated with insulin resistance, diabetes, and 
the metabolic syndrome.11 Because increased oxidative 
stress might play a role in the pathogenesis of hyperten-
sion, mechanistic studies should clarify why non-haem 
iron may be associated with lower blood pressure, or 
why the effects of haem and non-haem iron on blood 
pressure are different.
Even though INTERMAP is a high quality study, it 
highlights the difficulty in establishing a causal associa-
tion between a nutrient and a physiological outcome on 
the basis of a single observational study. The cross sec-
tional nature of INTERMAP precludes the possibility of 
sorting out the temporality of the observed associations. 
Perhaps more importantly, confounding effects by addi-
tional dietary and lifestyle variables are likely, because 
iron intake is correlated with other nutrients, foods, life-
style characteristics, and socioeconomic factors.
The observed effects could be the result of different 
dietary patterns—people who eat lots of red meat have a 
higher intake of haem iron than those with a more veg-
etarian diet, who take in more non-haem iron. Misclas-
sification of iron intake from dietary recall is substantial 
and may have biased the observed associations between 
iron and blood pressure. Because nutrients and foods are 
highly correlated and the errors in estimating nutrient 
intakes are also correlated, measurement error may bias 
the observed associations away from or towards the null. 
In addition, confidence intervals that do not take meas-
urement error into account probably under-represent the 
statistical uncertainty of the data.12
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 mechanistic studies in experimental models are needed 
to establish whether dietary iron has any effect on blood 
pressure levels.
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In their linked study, Nunn and colleagues report the 
results of a placebo controlled trial of co-trimoxazole 
prophylaxis in HIV positive Zambian adults being 
treated for tuberculosis. They found that co-trimoxa-
zole significantly reduced mortality (hazard ratio 0.79, 
95% confidence interval 0.63 to 0.99), and they con-
clude that the findings strengthen the evidence base for 
the World Health Organization and the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) guide-
lines issued in 2000.1 Despite the now overwhelming 
body of evidence the findings have been only partially 
translated into  practice.2-9
Prophylaxis with co-trimoxazole was used in indus-
trialised countries two decades before it appeared in 
Africa. In the early 1980s, co-trimoxazole was already 
being used to prevent bacterial infections in people with 
granulocytopenia who were HIV negative.
Why were American and European recommenda-
tions not transposed directly to Africa? Firstly, evidence 
indicated that pneumocystosis was rare in African 
adults. In contrast, HIV related bacterial diseases often 
caused death.10 Prophylaxis with co-trimoxazole, which 
was “primarily antiparasitic” in industrialised countries, 
therefore needed to become “predominantly antibac-
terial” in Africa. The implications of this functional 
shift in policy—especially the question of when to start 
prophylaxis—were not entirely clear. Secondly, some 
adults with HIV in industrialised countries were intoler-
ant of co-trimoxazole and had to interrupt treatment. 
In resource limited settings poor tolerance combined 
with more limited access to care might alter the risk to 
benefit ratio of the intervention. Finally, in Africa, HIV 
is often first diagnosed when patients start treatment for 
tuberculosis, and tuberculosis is the leading cause of 
death in patients with HIV.11 This explains why some 
studies specifically targeted such patients.
Two placebo controlled trials of co-trimoxazole in 
Côte d’Ivoire were published in 1999. One was carried 
out in adults with HIV being treated for  tuberculosis, 
with mortality as the primary outcome. It showed that 
co-trimoxazole reduced mortality by 46% (hazard ratio 
0.54, 95% confidence interval 0.38 to 0.77).9 The other 
study was in adults with HIV at WHO stage 2 or 3, 
with severe morbidity as the primary outcome. It 
showed that co-trimoxazole reduced severe  morbidity 
by 47% (hazard ratio 0.57, 95% confidence interval 
0.43 to 0.75).2 In both trials, co-trimoxazole was better 
tolerated than expected. In subgroup analyses both 
trials showed that the efficacy of co-trimoxazole was 
not restricted to patients with fewer than 200 CD4 cells 
×106/l.  Co-trimoxazole prevented malaria,  invasive 
bacterial diseases, and isosporiasis. The immediate 
 consequences of this evidence seemed logical. Firstly, 
two other African placebo controlled trials were 
stopped prematurely.  Secondly, WHO/UNAIDS 
experts  recommended that co-trimoxazole be part of 
the minimal package of care for African adults with 
fewer than 500 CD4 cells ×106/l.
Since 2000, policies on co-trimoxazole have 
 varied widely across the continent, ranging from no 
 prophylaxis to prophylaxis started at different CD4 
thresholds. The main argument for deciding not to 
 follow  standardised policies stemmed from the  question 
of whether  co-trimoxazole will work in countries 
where bacterial resistance to this drug may be higher 
than in Côte d’Ivoire. Between 2000 and 2008, six 
 non-randomised studies tackled this question. All found 
that the answer was “yes.”3-8 Further confirmation comes 
from Nunn and colleagues’ randomised trial.  Hopefully, 
their results will convince the very last sceptic. 
Bacterial diseases such as tuberculosis are curable 
in settings with high standards of care but cause death 
when access to diagnosis and treatment is limited.10-12 
This is why it is preferable to prevent these diseases. In 
sub-Saharan Africa, prophylaxis with co-trimoxazole 
and isoniazid are effective and these drugs should be 
prescribed. Trials are needed to assess their main alter-
native—starting antiretroviral therapy earlier.
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Around 500 000 people die in England each year, and 
this number is predicted to rise to around 530 000 by 
2030. Death affects every person, family, and commu-
nity, and every culture and creed has its own way of deal-
ing with it. We should all have an interest in good end of 
life care, yet death is not culturally acceptable, and it is a 
taboo subject to the public and the medical profession. 
In a recent BBC survey, only 34% of the general public 
reported that they had discussed their wishes for how 
they would like to die. Many healthcare professionals 
consider it a failure when patients die. In April 2008, the 
Heath Commission reported that no less than 54% of 
complaints related in some way to end of life care.
Last week the Department of Health published its strat-
egy for dealing with end of life care in the United King-
dom.1 Producing such a strategy is challenging because it 
incorporates health care, social care, spiritual care, and all 
possible sensitivities, as well as homeless people, prison-
ers, and mentally disabled people. More than 300 stake-
holders were consulted. We need to consider how end 
of life care should change, how the strategy will facilitate 
this, and how we can measure success.
Most people say they would prefer to die at home, 
yet the reality is that most deaths (58%) occur in NHS 
hospitals, with only 18% occurring at home, 17% in 
care homes, 4% in hospices, and 3% elsewhere.1 Where 
patients die is influenced by many factors.2 The complex-
ities of planning end of life care services are enormous. 
It is difficult to define exactly when end of life care starts 
and even more so to predict prognosis accurately.3 4
The strategy outlines a six step end of life care 
pathway, which begins with honest communica-
tion between clinician, patient, and carer, and the 
 identification of a trigger for discussion. Three themes 
underlie the six steps and continue throughout the 
pathway—support for carers and families, information, 
and spiritual services. However, the pathway is silent 
on the subject of psychological support, which is surely 
a key factor throughout the journey.
The report describes many examples of good practice 
and suggestions of care, but data to support the recom-
mendations are limited, and at present there are no mini-
mum standards.5 It does acknowledge the lack of good 
evidence and recommends that clinicians start pooling 
data, auditing practice, and developing metrics. It is only 
then that research will be able to evaluate the effects of 
new models on quality of care.
Assessments of the economics of care packages must 
include measures of quality of life, family satisfaction, 
and burden on the carer. Medical professionals like to 
think that they give patients control, but this impression 
is countered by evidence that patients do not die where 
they would prefer to.1 We must be able to test whether 
or not strategies are successful by including metrics, 
such as preferred place of care and preferred place of 
death, into patients’ recorded outcome measures. When 
these metrics have been determined they should also be 
made available to the palliative care team (perhaps on 
“personal dashboards,” which show in real time what 
is happening in terms of performance, as advocated by 
Professor Sir Bruce Keogh, NHS medical director). The 
natural competitiveness of clinicians might encourage 
them to improve their performance if the metrics show 
that their peers are doing better than they are.
High quality communication should be the essence of 
delivering the service, with the patient’s wishes and care 
plan available at every contact with the service. When-
ever an intervention of any sort occurs in primary care, 
secondary care, community services, or social services 
the patient’s exact wishes must be known and com-
plied with. The new strategy could make this happen 
by providing a contemporaneous document, and it is a 
challenge to the National Program for IT to show how 
such pathways can be enabled by electronically sharable 
documentation and plans.
Communication and training in symptom control 
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must be part of the core medical curriculum because the 
specialist palliative care workforce is relatively small.6 
Almost all healthcare professionals will at some time 
care for dying patients, and they should have the skills 
to do it well.
The main aims of this end of life care strategy are 
the delivery of high quality care, a change in culture, 
and  better communication, and this is reflected in the 
 proposed division of funds. A central Department of 
Health fund will support the necessary change in culture, 
linking public opinion and professional involvement. 
The  government is committed to spending an additional 
£286m (€360m; $570m) from 2009 to 2011, and it is 
refreshing to note that most of the funding will go to 
primary  care trusts, making real the policy of devolution 
of responsibility and resources to the front line. Trusts 
will be key players in devising and implementing new 
ways of  working.
Niall Dickson, chief executive of the Kings Fund, said 
of Lord Darzi’s reforms that “real cultural change will 
be needed in the health service if the vision is to be 
translated into a reality.”7 This applies in particular to 
this end of life care strategy. Dying has to become part 
of living, and we need to talk about it, plan for it, and 
encompass it. 
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consent for biobanking
Lack of dissent when opting in doesn’t necessarily support “opt out”
In the linked study, Johnsson and colleagues report levels 
of dissent in Swedish patients who are asked about stor-
age and future research use of samples collected during 
health care.1 Only 0.14% of patients dissented to either 
storage or use of their samples, and 0.063% confirmed 
their decision by completing a dissent form.
The authors conclude that their survey provides 
 evidence of high levels of trust in the Swedish system, 
and although this might not translate to other countries 
or contexts, it may support a move to opt-out systems 
of regulatory governance. Although the study  concerns 
samples rather than data derived from them, the research 
value of samples lies in the generalisable data that they 
can generate, so questions about control of information 
and access to it are crucial. The suggestion that lack of 
dissent in an explicit consent system (opt in) may  support 
a move to presumed consent (opt out) requires close 
scrutiny.
We need to decide what counts as evidence of support 
for biobanking practices, and more fundamentally, what 
counts as support for different regulatory mechanisms 
surrounding those practices. Central to answering these 
questions is the role and importance we give to consent 
as the legitimising factor in research and the handling of 
patient samples and records.
Respect for individual autonomy has become increas-
ingly emphasised in recent years,2 but it is often reduced 
to a crude imperative to obtain informed consent, and 
bears little relation to robust philosophical accounts of 
autonomy,3 which question whether fully informed con-
sent and patient empowerment through consent proc-
esses are achievable, and instead suggest a more modest 
role in protecting patients against deception or coercion. 
Moreover, over-reliance on a need for consent can thwart 
other valuable social ends, such as   scientifically robust 
medical research.
The obsession with the importance of consent, or 
“fetishisation” of consent, is seen across the entire range 
of biomedical activities. The Human Tissue Act 2004 
is replete with references to the need for “appropriate 
consent” without defining the term. In the context of 
secondary uses of data the mantra of “consent or ano-
nymise” guides the decisions of bodies such as the Patient 
Information Advisory Group in authorising research that 
uses patients’ data. Anonymising samples also avoids the 
need for consent for research samples in England and 
Wales, but only with appropriate ethical approval. The 
Human Tissue Authority recommends that “obtaining 
consent is preferable to developing complex systems for 
keeping samples unlinked.”4
The obsession with consent has been criticised in 
the context of using patient data for research because 
it is seen as an unduly restrictive means of governing 
research—consent is not always  practicable or possible 
to obtain. Furthermore, the law does not strictly require 
explicit consent, and the consent or anonymisation rule 
also has limits because it can undermine or even block 
valuable research.5 
Interestingly, legislation in Western Australia author-
ises the use of health data for research without the need 
for consent. Moreover, people cannot opt out because, as 
the guidance makes clear, “all Western Australians ben-
efit from reliable information about health.”6 In Europe, 
despite the rigours of the Data Protection Directive, offi-
cial opinion says that electronic health record systems 
that include provision for research—which are justified 
by substantial public interest—could feasibly be set up, as 
long as specific and suitable safeguards are in place, such 
as opt-out provision.7 It is possible, therefore, to envisage 
and implement systems of health related research that 
do not require explicit consent.
The matter of public support or approval of such 
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approaches is another matter. Johnsson and colleagues 
take as their starting premise that an option of dissent 
might undermine research and that this threat might be 
more likely if patients’ trust is eroding. They conclude 
that their results suggest that no immediate crisis of trust 
and so no immediate threat to research exists, at least in 
Sweden. It is not immediately obvious, however, why 
their results support a move to implied consent, or why 
that system would be better at tackling concerns—among 
the research community—that biobank research might 
be under threat.
If anything, the results of this study suggest that the cur-
rent system works to promote respect for research and 
patients. The authors lament the high costs and complex 
administration of an opt-in system “to support a small 
minority of patients” who would say no. However, they 
may be overlooking the costs of establishing a defensi-
ble opt-out system that gives patients adequate informa-
tion about who might have access to their samples or 
 information, and for what purposes.7 The need for an 
evidence base to support opt-out systems should not be 
underestimated. Although the Icelandic health sector 
database had widespread public support,8 the opt-out 
system was not accompanied by robust public education 
campaigns or public engagement exercises and caused 
considerable ethical controversy as a result.9
The position in the United Kingdom on evidence of 
support for opt-in or opt-out systems is fragmented. The 
Organ Donation Taskforce is currently investigating the 
viability of an opt-out system for transplants.10 In contrast, 
the recent independent evaluation of the Summary Care 
Record Early Adopter Programme has recommended 
an urgent review of the current implied consent (opt-
out) model, arguing that—for England at least—evidence 
exists of “widespread desire from patients and staff” for a 
simpler model of approval that requires explicit consent 
to view records.11 The tentative suggestion is that this bet-
ter reflects where patients put their trust—in people and 
not processes. The system in Scotland requires implied 
consent to create an “emergency care summary”—an 
electronic record of basic patient information available 
to all NHS Scotland staff caring for a patient when the 
general practitioner surgery is closed—with explicit con-
sent to view on each occasion; reports of dissent have 
been as low as 0.02% for this system.11
What is missing from much of the evidence base to 
date in the UK, Sweden, and elsewhere is a better under-
standing of what patients and the public understand 
about samples, records, and research; how well informed 
they are; and whether low opt-out rates truly reflect well 
placed trust or simply poorly informed apathy. In par-
ticular, we should be cautious about concluding that low 
rates of dissent in an opt-in system provide evidence of 
support for an opt-out system.
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A spate of knife killings in the United Kingdom, 
largely of young Londoners, has prompted outrage 
in the media, fear on the part of citizens, and new 
policy proposals from government. According to the 
authoritative British crime survey, weapons were used 
in around a quarter of violent incidents in England 
and Wales in 2006-7, although the survey does not 
take account of crime  affecting  people under 16 years.1 
According to this source, the annual prevalence of 
knife use has remained constant at around 7% of all 
violent incidents since 2000. Hospital episode  statistics 
show that rates of hospital admission in England after 
violence of all types increased (from 82.7/100 000 
population in 2000-1 to 114.4/100 000 in 2006-7) at 
almost exactly the same rate as admissions after knife 
violence (from 8.5/100 000 to 11.3/100 000). In con-
trast, rates of treatment in emergency departments 
after violence of all types decreased from about 850 
to 620 per 100 000 over the same time2; no national 
emergency department data are available on knife 
 violence specifically. In summary, since 2000,  violence 
in England and Wales has become less frequent, 
but injuries may have become more serious, which 
could explain the increase in hospital admissions. 
However, this increase could also reflect changes in 
admission policy, such as efforts to reduce emergency 
 department trolley waits.
Proportions of knife violence in the United States 
(6.3% of all 2006 violence identified in the US 
national crime victimisation survey) are remarkably 
similar to those in the UK.3 Elsewhere, the inter-
national crime victimisation survey (which brings 
188   BMJ | 26 July 2008 | VoluMe 337
eDITORIaLs
together crime  survey data from 28 countries) indi-
cates that rates of knife violence are  highest in Spain 
and Portugal and lowest in Scandinavian countries 
and Greece.4
People carry weapons for four main reasons—to 
increase their capacity to cause harm,5 because of 
fear of violence,6 to facilitate robbery,5 and to dem-
onstrate “machismo.”7 The availability of weapons 
and the act of carrying them also determine their use. 
For example, the availability of handguns is a major 
determinant of deaths from firearms.8 As far as crimi-
nal justice interventions are concerned, increasing 
the perceived likelihood of being caught is a more 
effective deterrent than severity of sentence.8 Police 
interventions that target violence “hotspots” are also 
effective.9 In the absence of objective evaluations of 
interventions designed to reduce knife crime specifi-
cally, rational prevention policy should be based on 
these findings.
Restorative justice—where offenders are confronted 
with the consequences of their actions in conferences 
that include community representatives, the police, 
and their victims and which result in a heartfelt 
apology—reduces repeat violence.10 Fear of violence 
is known to be increased by evidence of criminal 
damage,  litter, and graffiti11—in effect, a disfigured 
environment sends messages that personal disfigure-
ment may be next. Environmental interventions are 
therefore likely to reduce fear. Because the motiva-
tion for most robbery is related to drugs, tackling 
drug use and markets will probably reduce the car-
rying of weapons.
Demonstrations of machismo are used by assail-
ants to dissuade victims from reporting violence to 
the police. Many violent incidents that result in medi-
cal treatment are not reported to the police because 
patients are afraid of reprisals, they are unable to 
identify assailants, or they are unwilling to have their 
own conduct  scrutinised. Emergency departments 
can help by collecting anonymised data on the loca-
tions and times that violent events occur and the 
types of weapons used, and by sharing these data 
with crime reduction agencies. Clearly, unless vio-
lence hotspots are identified, they cannot be targeted. 
It is not safe to assume that the most serious vio-
lence, including knife and gun violence, will have 
been reported.12
UK legislation on violent crime in the past 
10 years has done much to promote data 
 sharing, including the introduction of more than 
350  statutory Crime Reduction Partnerships 
( Community Safety  Partnerships in Wales and 
Scotland) to which the NHS, local authorities, and 
the police must contribute. Evaluations provide 
evidence that this integrated approach significantly 
reduces  violence compared with the police and 
local  authorities working alone.13 The unique data 
derived from emergency departments and the influ-
ence of  emergency department consultants working 
in these  partnerships have emerged as distinctive 
and effective NHS  contributions.
If the patient or other people are at risk of further 
violence, the police should be contacted promptly 
and directly—with the consent of the patient if 
 possible, but without this if necessary. Here, as with 
child  protection, discretion is needed, but some 
 assessment of risk of  further harm is necessary in all 
health  services in which adults and children who are 
injured in  violence are treated.
Measures that decrease the availability of knives, 
including criminalisation of knife carrying, are 
also rational. Metal detector wands and arches at 
 strategic street and public transport locations may 
be effective.14 More strategically, violence is now 
 recognised by the World Health Organization as a 
global  public health problem and a barrier to inter-
national  development.15
The lack of evidence of effectiveness of specific 
measures to tackle knife crime exemplifies that, 
 compared with medical science, the evidence base 
for the crime sciences is in its infancy. Whereas 
medicine is underpinned by rigorous applied 
research integrated with practitioner training in 
university schools, police, probation, and prison 
services lack these foundations. In the 19th century, 
Sir  William Osler successfully demanded an “inva-
sion of hospitals” by universities, paving the way 
for the  exponential increase in clinical experiments 
and much more effective health care in the next 
 century. It is high time our best universities invaded 
the criminal justice system.
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